Eighty-nine HIV-@-infected antiretroviral-naive patients with < @ CD@ cells per cubic millimeter were randomly assigned in a @:@:@ ratio to efavirenz ( n = @ ) , atazanavir/ritonavir ( n = @ ) , or lopinavir/ritonavir ( n = @ ) combined with tenofovir plus emtricitabine .